The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy - Summary - MDSpire

The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy

  • By

  • Wendy A. Brown

  • Priya Sumithran

  • Michael Cowley

  • Ricardo Cohen

  • Carel Le Roux

  • Philip Schauer

  • Santosh Agarwal

  • Jamie Ard

  • Camilo Boza

  • Jenny Lynn Cargiuolo

  • Letizia Ceccarelli

  • Jake Coverdale

  • Brian Dunkin

  • Francis Finucane

  • Kapil Gupta

  • Lee M. Kaplan

  • Marina Kurian

  • Ildiko Lingvay

  • Alex Miras

  • Chuck Pearlman

  • Terissa Petry

  • Dimitri Pournaras

  • Jonthan Purnell

  • Roxana Ruiz

  • Carlos Schiavon

  • Abd Tahrani

  • Hanan Tarek

  • Jorg Tomaszewski

  • Sascha Tumik

  • Ramy Younes

  • May 4, 2026

  • 0 min

Share

Objective:

To identify specific knowledge gaps and relevant research questions regarding the combined use of obesity management medications (OMM), metabolic bariatric surgery (MBS), and endoscopic therapies.

Key Findings:
  • New obesity medications like semaglutide and tirzepatide show significant weight loss, with clinical trials indicating a mean weight loss of 15-25%, narrowing the gap between medical and surgical management.
  • There is a need for further research on the safety and efficacy of combining OMM with MBS, particularly in diverse patient populations.
  • Previous studies indicate potential benefits of OMM post-MBS, but data on long-term outcomes and patient acceptability remain limited.
Interpretation:

The integration of pharmacological and surgical approaches in obesity management is promising, but urgent further research is essential to optimize treatment strategies and improve patient outcomes.

Limitations:
  • Limited data on the long-term efficacy and safety of combination therapies, particularly in diverse populations.
  • Few randomized controlled trials have explored the combined use of OMM and MBS, highlighting a significant research gap.
  • Lack of consensus on preoperative use of OMM or endoscopic therapies, which complicates treatment planning.
Conclusion:

A comprehensive approach combining OMM, MBS, and endoscopic therapies may enhance obesity management, but further investigation is crucial to establish effective treatment protocols and improve patient outcomes.

Original Source(s)

The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy

  • by Wendy A. Brown, Priya Sumithran, Michael Cowley, Ricardo Cohen, Carel Le Roux, Philip Schauer, Santosh Agarwal, Jamie Ard, Camilo Boza, Jenny Lynn Cargiuolo, Letizia Ceccarelli, Jake Coverdale, Brian Dunkin, Francis Finucane, Kapil Gupta, Lee M. Kaplan, Marina Kurian, Ildiko Lingvay, Alex Miras, Chuck Pearlman, Terissa Petry, Dimitri Pournaras, Jonthan Purnell, Roxana Ruiz, Carlos Schiavon, Abd Tahrani, Hanan Tarek, Jorg Tomaszewski, Sascha Tumik, Ramy Younes

  • May 4, 2026

Related Content

Laparoscopic Roux-en-Y Gastric Bypass with the Maestro™ System: a Novel Collaborative Robotic Platform

Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population

Robotic hand-sewn vs. laparoscopic linear-stapled Roux-en-Y gastric bypass: a propensity score-matched analysis of primary and conversion cases